Cowen & Co. Maintains a Hold Rating on GlaxoSmithKline (GSK)

By Ryan Adsit

In a report released today, Steve Scala from Cowen & Co. maintained a Hold rating on GlaxoSmithKline (GSKResearch Report), with a price target of $45. The company’s shares closed on Friday at $39.80.

Scala has an average return of 6.3% when recommending GlaxoSmithKline.

According to, Scala is ranked #1019 out of 5191 analysts.

Currently, the analyst consensus on GlaxoSmithKline is a Hold with an average price target of $45.

See today’s analyst top recommended stocks >>

Based on GlaxoSmithKline’s latest earnings release for the quarter ending March 31, the company reported a quarterly net profit of $1.08 billion. In comparison, last year the company had a net profit of $764 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

GlaxoSmithKline Plc is a global healthcare company which engages in researching, developing and manufacturing of pharmaceutical medicines, vaccines and consumer healthcare products. It operates through the following four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.